首页 > 最新文献

International Journal of Pharmaceutics最新文献

英文 中文
Delivery of imiquimod to intestinal lymph nodes following oral administration 口服咪喹莫特后向肠道淋巴结输送。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-31 DOI: 10.1016/j.ijpharm.2024.124895
Haojie Chen , Liuhang Ji , Abigail Wong , Yenju Chu , Wanshan Feng , Yufei Zhu , Junting Wang , Eleonora Comeo , Dong-Hyun Kim , Michael J. Stocks , Pavel Gershkovich
Intestinal lymph nodes are involved in the progression of colorectal cancer (CRC). Tumours suppress the activation of dendritic cells (DCs) in draining lymph nodes, diminishing anti-cancer immune response. Imiquimod (IMQ) facilitates DCs activation via toll-like receptor 7, suggesting that targeted delivery of IMQ to intestinal lymph nodes can improve the treatment of CRC. This study aims to enhance the delivery of IMQ to intestinal lymph nodes by a highly lipophilic prodrug approach. Amide prodrugs were synthesised by conjugating IMQ with saturated and unsaturated medium- to long-chain fatty acids. Their potential for intestinal lymphatic transport was assessed by their affinity to chylomicrons and solubility in long-chain triglycerides. Further selection of prodrug candidates was determined by resistance to enzymatic hydrolysis in intestinal lumen and release of IMQ in the lymphatics using fasting state simulated intestinal fluid supplemented with esterases, brush border enzyme vesicles and plasma. Key pharmacokinetic parameters and biodistribution in rats were assessed for the most promising compounds, prodrugs 5 and 8. The plasma concentration–time profile of IMQ following oral administration of the prodrugs was less erratic in comparison to the administration of unmodified IMQ. The lymph-to-plasma ratios of IMQ concentration increased 1.9- and 1.7-fold using prodrugs 5 and 8 in comparison to administration of unmodified IMQ, respectively. Importantly, the average concentration of IMQ in mesenteric lymph nodes (MLN) was 11.2- and 7.6-fold higher than in plasma following the administration of prodrugs 5 and 8, respectively. Additionally, the non-specific wide distribution of IMQ into various organs and tissues was reduced with prodrugs. This work suggests that the highly lipophilic prodrug approach can efficiently deliver IMQ to intestinal lymphatics. In addition, this study demonstrates the feasibility of an amide prodrug approach for intestinal lymphatic targeting.
肠道淋巴结与结直肠癌(CRC)的进展有关。肿瘤会抑制引流淋巴结中树突状细胞(DC)的活化,从而削弱抗癌免疫反应。咪喹莫特(IMQ)可通过收费样受体7促进树突状细胞的活化,这表明向肠淋巴结靶向递送IMQ可改善对CRC的治疗。本研究旨在通过一种高亲脂性原药的方法,加强IMQ向肠淋巴结的递送。通过将 IMQ 与饱和及不饱和中长链脂肪酸共轭,合成了酰胺原药。这些原药与乳糜微粒的亲和力以及在长链甘油三酯中的溶解度评估了它们在肠道淋巴运输方面的潜力。利用空腹状态下的模拟肠液,并辅以酯酶、刷状边界酶囊和血浆,通过对肠腔内酶水解的耐受性和 IMQ 在淋巴管中的释放情况,进一步筛选出候选原药。对最有前景的化合物、原药 5 和 8 的主要药代动力学参数和在大鼠体内的生物分布进行了评估。与口服未改性的 IMQ 相比,口服原药后 IMQ 的血浆浓度-时间曲线波动较小。与服用未改性的 IMQ 相比,使用原药 5 和 8 后 IMQ 的淋巴-血浆浓度比分别增加了 1.9 倍和 1.7 倍。重要的是,使用原药 5 和 8 后,肠系膜淋巴结(MLN)中的 IMQ 平均浓度分别是血浆中的 11.2 倍和 7.6 倍。此外,原药还减少了 IMQ 在各器官和组织中的非特异性广泛分布。这项工作表明,高亲脂性原药方法可以有效地将 IMQ 送入肠道淋巴管。此外,这项研究还证明了酰胺原药方法用于肠道淋巴靶向的可行性。
{"title":"Delivery of imiquimod to intestinal lymph nodes following oral administration","authors":"Haojie Chen ,&nbsp;Liuhang Ji ,&nbsp;Abigail Wong ,&nbsp;Yenju Chu ,&nbsp;Wanshan Feng ,&nbsp;Yufei Zhu ,&nbsp;Junting Wang ,&nbsp;Eleonora Comeo ,&nbsp;Dong-Hyun Kim ,&nbsp;Michael J. Stocks ,&nbsp;Pavel Gershkovich","doi":"10.1016/j.ijpharm.2024.124895","DOIUrl":"10.1016/j.ijpharm.2024.124895","url":null,"abstract":"<div><div>Intestinal lymph nodes are involved in the progression of colorectal cancer (CRC). Tumours suppress the activation of dendritic cells (DCs) in draining lymph nodes, diminishing anti-cancer immune response. Imiquimod (IMQ) facilitates DCs activation <em>via</em> toll-like receptor 7, suggesting that targeted delivery of IMQ to intestinal lymph nodes can improve the treatment of CRC. This study aims to enhance the delivery of IMQ to intestinal lymph nodes by a highly lipophilic prodrug approach. Amide prodrugs were synthesised by conjugating IMQ with saturated and unsaturated medium- to long-chain fatty acids. Their potential for intestinal lymphatic transport was assessed by their affinity to chylomicrons and solubility in long-chain triglycerides. Further selection of prodrug candidates was determined by resistance to enzymatic hydrolysis in intestinal lumen and release of IMQ in the lymphatics using fasting state simulated intestinal fluid supplemented with esterases, brush border enzyme vesicles and plasma. Key pharmacokinetic parameters and biodistribution in rats were assessed for the most promising compounds, prodrugs 5 and 8. The plasma concentration–time profile of IMQ following oral administration of the prodrugs was less erratic in comparison to the administration of unmodified IMQ. The lymph-to-plasma ratios of IMQ concentration increased 1.9- and 1.7-fold using prodrugs 5 and 8 in comparison to administration of unmodified IMQ, respectively. Importantly, the average concentration of IMQ in mesenteric lymph nodes (MLN) was 11.2- and 7.6-fold higher than in plasma following the administration of prodrugs 5 and 8, respectively. Additionally, the non-specific wide distribution of IMQ into various organs and tissues was reduced with prodrugs. This work suggests that the highly lipophilic prodrug approach can efficiently deliver IMQ to intestinal lymphatics. In addition, this study demonstrates the feasibility of an amide prodrug approach for intestinal lymphatic targeting.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124895"},"PeriodicalIF":5.3,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative cancer therapy: Unleashing the potential of macromolecule-loaded mesoporous bioactive glasses for precision diagnosis and treatment 创新癌症疗法:释放大分子介孔生物活性玻璃的潜力,实现精准诊断和治疗。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-30 DOI: 10.1016/j.ijpharm.2024.124847
Ali Mohammad Amani , Lobat Tayebi , Ehsan Vafa , Reza Bazargan-Lari , Milad Abbasi , Ahmad Vaez , Hesam Kamyab , Lalitha Gnanasekaran , Shreeshivadasan Chelliapan , Mohammad Javad Azizli
Cancer continues to pose a formidable threat, claiming millions of lives annually. A beacon of hope in this battle lies in the realm of bioactive glasses, which have undergone a remarkable evolution over the past five decades. Among these, mesoporous bioactive glasses (MBGs) emerge as a dynamic subset endowed with customizable attributes such as high surface area and porosity. While holding immense promise for cancer care, the full clinical potential of MBGs remains largely unexplored. This review delves into the cutting-edge advancements in MBG technology, illuminating their pivotal role in cancer management – spanning from early detection to targeted therapeutic interventions like photothermal and photodynamic treatments. Furthermore, the molecular mechanisms underpinning MBGs’ anticancer properties are elucidated, alongside an exploration of existing limitations in their application. Through this comprehensive synthesis, the significance of MBGs in revolutionizing cancer therapy is underscored, underscoring the urgent need for continued research to unlock their full potential in reshaping the landscape of cancer care.
癌症仍然是一个巨大的威胁,每年夺走数百万人的生命。生物活性玻璃是这场战争中的一盏希望之灯,在过去的五十年里,生物活性玻璃经历了显著的发展。其中,介孔生物活性玻璃(MBGs)是一个充满活力的子集,具有可定制的特性,如高比表面积和多孔性。虽然介孔生物活性玻璃在癌症治疗方面大有可为,但其全部临床潜力在很大程度上仍未得到开发。本综述深入探讨了 MBG 技术的前沿进展,阐明了它们在癌症治疗中的关键作用--从早期检测到光热和光动力治疗等靶向治疗干预。此外,还阐明了支持 MBG 抗癌特性的分子机制,并探讨了其应用中的现有局限性。通过这份全面的综述,我们强调了 MBGs 在彻底改变癌症疗法方面的重要意义,并强调迫切需要继续开展研究,以充分挖掘 MBGs 在重塑癌症治疗格局方面的潜力。
{"title":"Innovative cancer therapy: Unleashing the potential of macromolecule-loaded mesoporous bioactive glasses for precision diagnosis and treatment","authors":"Ali Mohammad Amani ,&nbsp;Lobat Tayebi ,&nbsp;Ehsan Vafa ,&nbsp;Reza Bazargan-Lari ,&nbsp;Milad Abbasi ,&nbsp;Ahmad Vaez ,&nbsp;Hesam Kamyab ,&nbsp;Lalitha Gnanasekaran ,&nbsp;Shreeshivadasan Chelliapan ,&nbsp;Mohammad Javad Azizli","doi":"10.1016/j.ijpharm.2024.124847","DOIUrl":"10.1016/j.ijpharm.2024.124847","url":null,"abstract":"<div><div>Cancer continues to pose a formidable threat, claiming millions of lives annually. A beacon of hope in this battle lies in the realm of bioactive glasses, which have undergone a remarkable evolution over the past five decades. Among these, mesoporous bioactive glasses (MBGs) emerge as a dynamic subset endowed with customizable attributes such as high surface area and porosity. While holding immense promise for cancer care, the full clinical potential of MBGs remains largely unexplored. This review delves into the cutting-edge advancements in MBG technology, illuminating their pivotal role in cancer management – spanning from early detection to targeted therapeutic interventions like photothermal and photodynamic treatments. Furthermore, the molecular mechanisms underpinning MBGs’ anticancer properties are elucidated, alongside an exploration of existing limitations in their application. Through this comprehensive synthesis, the significance of MBGs in revolutionizing cancer therapy is underscored, underscoring the urgent need for continued research to unlock their full potential in reshaping the landscape of cancer care.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124847"},"PeriodicalIF":5.3,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancement in the nose-to-brain drug delivery of FDA-approved drugs for the better management of depression and psychiatric disorders. 推进美国食品及药物管理局(FDA)批准的鼻脑给药技术,更好地治疗抑郁症和精神疾病。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-30 DOI: 10.1016/j.ijpharm.2024.124866
Rajshekher Upadhyay, Pappu Ghosh, Madhuri Desavathu

The Prevalence of Depressive and Psychiatric disorders is increasing globally, and despite the availability of numerous FDA-approved drugs, treatment remains challenging. Many conventional antidepressants and antipsychotic formulations face issues such as low solubility, high first-pass metabolism, poor bioavailability, inadequate blood-brain barrier penetration, and systemic side effects. These challenges lead to reduced efficacy, slower onset of action, and decreased patient adherence to treatment. To address these problems, recent studies have explored the nose-to-brain route for drug delivery. This method offers several advantages, including non-invasive drug administration, direct access to the brain, rapid onset of action, reduced systemic exposure and side effects, avoidance of first-pass metabolism, enhanced bioavailability, precision dosing, and improved patient compliance. The formulations used for this approach include lipidic nanoparticles, polymeric nanoparticles, nasal gels, cubosomes, niosomes, polymeric micelles, nanosuspensions, nanoemulsions, nanocapsules, and elastosomes. This review analyzes and summarizes the published work on the nose-to-brain delivery of FDA-approved antidepressants and antipsychotic drugs, with a focus on the preparation, characterization, pharmacokinetics, pharmacodynamics, and toxicity profiling of these nanoformulations.

抑郁症和精神疾病的发病率在全球范围内不断上升,尽管美国食品及药物管理局已批准了多种药物,但治疗仍然充满挑战。许多传统的抗抑郁剂和抗精神病制剂都面临着溶解度低、首过代谢率高、生物利用度低、血脑屏障渗透不足以及全身副作用等问题。这些问题导致药效降低、起效较慢以及患者对治疗的依从性下降。为了解决这些问题,最近的研究探索了鼻脑给药途径。这种方法具有多种优势,包括无创给药、直接进入大脑、起效迅速、减少全身暴露和副作用、避免首过代谢、提高生物利用度、精确给药和改善患者依从性。这种方法使用的制剂包括脂质纳米颗粒、聚合物纳米颗粒、鼻凝胶、立方体、niosomes、聚合物胶束、纳米悬浮剂、纳米乳剂、纳米胶囊和弹性体。本综述分析并总结了已发表的有关经 FDA 批准的抗抑郁药物和抗精神病药物从鼻腔向大脑给药的研究成果,重点关注这些纳米制剂的制备、表征、药代动力学、药效学和毒性分析。
{"title":"Advancement in the nose-to-brain drug delivery of FDA-approved drugs for the better management of depression and psychiatric disorders.","authors":"Rajshekher Upadhyay, Pappu Ghosh, Madhuri Desavathu","doi":"10.1016/j.ijpharm.2024.124866","DOIUrl":"https://doi.org/10.1016/j.ijpharm.2024.124866","url":null,"abstract":"<p><p>The Prevalence of Depressive and Psychiatric disorders is increasing globally, and despite the availability of numerous FDA-approved drugs, treatment remains challenging. Many conventional antidepressants and antipsychotic formulations face issues such as low solubility, high first-pass metabolism, poor bioavailability, inadequate blood-brain barrier penetration, and systemic side effects. These challenges lead to reduced efficacy, slower onset of action, and decreased patient adherence to treatment. To address these problems, recent studies have explored the nose-to-brain route for drug delivery. This method offers several advantages, including non-invasive drug administration, direct access to the brain, rapid onset of action, reduced systemic exposure and side effects, avoidance of first-pass metabolism, enhanced bioavailability, precision dosing, and improved patient compliance. The formulations used for this approach include lipidic nanoparticles, polymeric nanoparticles, nasal gels, cubosomes, niosomes, polymeric micelles, nanosuspensions, nanoemulsions, nanocapsules, and elastosomes. This review analyzes and summarizes the published work on the nose-to-brain delivery of FDA-approved antidepressants and antipsychotic drugs, with a focus on the preparation, characterization, pharmacokinetics, pharmacodynamics, and toxicity profiling of these nanoformulations.</p>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":" ","pages":"124866"},"PeriodicalIF":5.3,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanostructured biloalbuminosomes loaded with berberine and berberrubine for Alleviating heavy Metal-Induced male infertility in rats 负载有小檗碱和小檗红碱的纳米结构双白蛋白体用于缓解重金属诱导的大鼠雄性不育症。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-30 DOI: 10.1016/j.ijpharm.2024.124892
Aya M. Helal , Mona M. Yossef , Inas K. Seif , Mohamed Abd El-Salam , Maha A. El Demellawy , Shaymaa A. Abdulmalek , Ahmed Z. Ghareeb , Jasmine Holail , Abdulaziz Mohsen Al-mahallawi , Sally A. El-Zahaby , Doaa A Ghareeb
Despite the remarkable biological effects of berberine (BBR), particularly on fertility, its bioavailability is low. This study aims to test the effectiveness of novel nanostructured biloalbuminosomes (BILS) of BBR and its metabolite berberrubine (M1) in treatment of testicular and prostatic lesions. M1 was semi-synthesized from BBR using microwave-assisted reaction. The solvent evaporation method was used to prepare BBR-BILS and M1-BILS by three different concentrations of sodium cholate (SC) or glycocholate (SG), along with the incorporation of bovine serum albumin (BSA). The prepared BILS were fully characterized. Male infertility was induced by cadmium (Cd) at 5 mg/kg and lead (Pb) at 20 mg/kg contaminated water for 90 days, followed by treatment with BBR, M1, and their BILS (BBR-BILS and M1-BILS) for 45 days. Blood male infertility markers, testicular and prostatic oxidative stress status, autophagy, inflammation, along with testicular and prostatic concentrations of Cd and Pb, and histopathology of both tested tissues were determined using standardized protocols. The optimal BBR-BILS and M1-BILS nano-preparations, containing 30 mg SC, were chosen based on the best characterization properties of the preparations. Both nano-preparations improved heavy metals-induced testicular and prostatic deformities, as they reduced Bax and elevated Bcl-2 expressions in both tissues. Moreover, they activated the mTOR/PI3K pathway with a marked reduction in AMPK and activated LC-3II protein levels. Consequently, testicular and prostatic architecture and functions were improved. This study is the first to report the preparation of BBR and M1 BILS nano-preparations and proved their superior efficacy compared to free drugs against testicular and prostatic deformities by attenuating oxidative stress-induced excessive autophagy, offering a new hope to manage male infertility.
尽管小檗碱(BBR)具有显著的生物效应,尤其是对生育力的影响,但其生物利用度却很低。本研究旨在测试新型纳米结构的小檗碱及其代谢物小檗碱(M1)双白蛋白体(BILS)在治疗睾丸和前列腺病变方面的有效性。M1 是利用微波辅助反应从 BBR 半合成的。通过三种不同浓度的胆酸钠(SC)或甘胆酸盐(SG)以及牛血清白蛋白(BSA),采用溶剂蒸发法制备了 BBR-BILS 和 M1-BILS。制备的 BILS 具有全面的特征。用镉 (Cd) 5 mg/kg 和铅 (Pb) 20 mg/kg 污染的水诱导男性不育症 90 天,然后用 BBR、M1 及其 BILS(BBR-BILS 和 M1-BILS)处理 45 天。采用标准化方案测定血液中的男性不育症指标、睾丸和前列腺的氧化应激状态、自噬作用、炎症、睾丸和前列腺中的镉和铅浓度以及两种受测组织的组织病理学。根据制剂的最佳表征特性,选择了含有 30 毫克 SC 的最佳 BBR-BILS 和 M1-BILS 纳米制剂。这两种纳米制剂都能改善重金属诱导的睾丸和前列腺畸形,因为它们降低了这两种组织中 Bax 的表达,提高了 Bcl-2 的表达。此外,它们还激活了 mTOR/PI3K 通路,显著降低了 AMPK 的水平,并激活了 LC-3II 蛋白水平。因此,睾丸和前列腺的结构和功能都得到了改善。这项研究首次报道了 BBR 和 M1 BILS 纳米制剂的制备方法,并证明了与游离药物相比,它们通过抑制氧化应激诱导的过度自噬,对睾丸和前列腺畸形有更好的疗效,为治疗男性不育症带来了新希望。
{"title":"Nanostructured biloalbuminosomes loaded with berberine and berberrubine for Alleviating heavy Metal-Induced male infertility in rats","authors":"Aya M. Helal ,&nbsp;Mona M. Yossef ,&nbsp;Inas K. Seif ,&nbsp;Mohamed Abd El-Salam ,&nbsp;Maha A. El Demellawy ,&nbsp;Shaymaa A. Abdulmalek ,&nbsp;Ahmed Z. Ghareeb ,&nbsp;Jasmine Holail ,&nbsp;Abdulaziz Mohsen Al-mahallawi ,&nbsp;Sally A. El-Zahaby ,&nbsp;Doaa A Ghareeb","doi":"10.1016/j.ijpharm.2024.124892","DOIUrl":"10.1016/j.ijpharm.2024.124892","url":null,"abstract":"<div><div>Despite the remarkable biological effects of berberine (BBR), particularly on fertility, its bioavailability is low. This study aims to test the effectiveness of novel nanostructured biloalbuminosomes (BILS) of BBR and its metabolite berberrubine (M1) in treatment of testicular and prostatic lesions. M1 was semi-synthesized from BBR using microwave-assisted reaction. The solvent evaporation method was used to prepare BBR-BILS and M1-BILS by three different concentrations of sodium cholate (SC) or glycocholate (SG), along with the incorporation of bovine serum albumin (BSA). The prepared BILS were fully characterized. Male infertility was induced by cadmium (Cd) at 5 mg/kg and lead (Pb) at 20 mg/kg contaminated water for 90 days, followed by treatment with BBR, M1, and their BILS (BBR-BILS and M1-BILS) for 45 days. Blood male infertility markers, testicular and prostatic oxidative stress status, autophagy, inflammation, along with testicular and prostatic concentrations of Cd and Pb, and histopathology of both tested tissues were determined using standardized protocols. The optimal BBR-BILS and M1-BILS nano-preparations, containing 30 mg SC, were chosen based on the best characterization properties of the preparations. Both nano-preparations improved heavy metals-induced testicular and prostatic deformities, as they reduced Bax and elevated Bcl-2 expressions in both tissues. Moreover, they activated the mTOR/PI3K pathway with a marked reduction in AMPK and activated LC-3II protein levels. Consequently, testicular and prostatic architecture and functions were improved. This study is the first to report the preparation of BBR and M1 BILS nano-preparations and proved their superior efficacy compared to free drugs against testicular and prostatic deformities by attenuating oxidative stress-induced excessive autophagy, offering a new hope to manage male infertility.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124892"},"PeriodicalIF":5.3,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computer-Aided formulation design for pharmaceutical drug product development, part 01: Materials exploration through a visualization tool. 用于药物产品开发的计算机辅助配方设计,第 01 部分:通过可视化工具探索材料。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-29 DOI: 10.1016/j.ijpharm.2024.124891
Patrick M Piccione, Moritz N Lang, Felipe Amado Becker, Albert Hofstetter, Stéphanie Marchal, Kevin Ly, Valentin Legras, Andreas Ewert, David Kohler, Reto Maurer, Nina Willecke, Ryan Burwood, Paul Kroll

An interactive tool has been developed to help design oral solid dosage form formulations. The tool enables quantitative explorations and comparisons of physical, bulk, and mechanical properties, and takes into account functional characteristics as well. In this manner, comparisons and clustering of both excipients and APIs can be carried out. These comparisons enable the generation of alternatives as well as surrogate identification, so as to spare resources and material. Multiple data sources were merged to create a "joint" data table with all relevant properties. Four main workflow activities are supported: Explore Materials, Search Similar APIs, Search Similar Excipients and Search Material Clusters. Multi-dimensional filtering can be superimposed to each functionality. Suggested visualizations are made particularly accessible by providing them as "standard plots". The underlying philosophy is to empower formulation scientists to explore options, rather than prescribe decisions on exclusively mathematical grounds. The tool described here is the first step towards a holistic optimization incorporating predictions of mixture properties. Methodology of use is illustrated through three material selection application examples.

我们开发了一种交互式工具来帮助设计口服固体制剂配方。该工具可对物理、体积和机械性能进行定量探索和比较,并将功能特性考虑在内。通过这种方式,可以对辅料和原料药进行比较和分组。通过这些比较,可以生成替代品并进行替代品鉴定,从而节省资源和材料。合并多个数据源,创建一个包含所有相关属性的 "联合 "数据表。支持四个主要工作流程活动:探索材料、搜索类似原料药、搜索类似辅料和搜索材料集群。每种功能都可以叠加多维过滤。通过以 "标准图 "的形式提供建议的可视化效果,使其特别易于使用。该工具的基本理念是让制剂科学家能够探索各种选项,而不是完全根据数学原理做出决定。这里介绍的工具是实现包含混合物特性预测的整体优化的第一步。通过三个材料选择应用实例说明了使用方法。
{"title":"Computer-Aided formulation design for pharmaceutical drug product development, part 01: Materials exploration through a visualization tool.","authors":"Patrick M Piccione, Moritz N Lang, Felipe Amado Becker, Albert Hofstetter, Stéphanie Marchal, Kevin Ly, Valentin Legras, Andreas Ewert, David Kohler, Reto Maurer, Nina Willecke, Ryan Burwood, Paul Kroll","doi":"10.1016/j.ijpharm.2024.124891","DOIUrl":"https://doi.org/10.1016/j.ijpharm.2024.124891","url":null,"abstract":"<p><p>An interactive tool has been developed to help design oral solid dosage form formulations. The tool enables quantitative explorations and comparisons of physical, bulk, and mechanical properties, and takes into account functional characteristics as well. In this manner, comparisons and clustering of both excipients and APIs can be carried out. These comparisons enable the generation of alternatives as well as surrogate identification, so as to spare resources and material. Multiple data sources were merged to create a \"joint\" data table with all relevant properties. Four main workflow activities are supported: Explore Materials, Search Similar APIs, Search Similar Excipients and Search Material Clusters. Multi-dimensional filtering can be superimposed to each functionality. Suggested visualizations are made particularly accessible by providing them as \"standard plots\". The underlying philosophy is to empower formulation scientists to explore options, rather than prescribe decisions on exclusively mathematical grounds. The tool described here is the first step towards a holistic optimization incorporating predictions of mixture properties. Methodology of use is illustrated through three material selection application examples.</p>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":" ","pages":"124891"},"PeriodicalIF":5.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metal ion formulations for diabetic wound healing: Mechanisms and therapeutic potential 用于糖尿病伤口愈合的金属离子制剂:机理与治疗潜力。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-29 DOI: 10.1016/j.ijpharm.2024.124889
Yuhe Dai , Qianbo Zhang , Rifang Gu , Jitao Chen , Penghui Ye , Huan Zhu , Ming Tang , Xuqiang Nie
Metals are vital in human physiology, which not only act as enzyme catalysts in the processes of superoxide dismutase and glucose phosphorylation, but also affect the redox process, osmotic adjustment, metabolism and neural signals. However, metal imbalances can lead to diseases such as diabetes, which is marked by chronic hyperglycemia and affects wound healing. The hyperglycemic milieu of diabetes impairs wound healing, posing significant challenges to patient quality of life. Wound healing encompasses a complex cascade of hemostasis, inflammation, proliferation, and remodeling phases, which are susceptible to disruption in hyperglycemic conditions. In recent decades, metals have emerged as critical facilitators of wound repair by enhancing antimicrobial properties (e.g., iron and silver), providing angiogenic stimulation (copper), promoting antioxidant activity and growth factor synthesis (zinc), and supporting wound closure (calcium and magnesium). Consequently, research has pivoted towards the development of metal ion-based therapeutics, including innovative formulations such as nano-hydrogels, nano-microneedle dressings, and microneedle patches. Prepared by combining macromolecular materials such as chitosan, hyaluronic acid and sodium alginate with metals, aiming at improving the management of diabetic wounds. This review delineates the roles of key metals in human physiology and evaluates the application of metal ions in diabetic wound management strategies.
金属在人体生理中至关重要,它不仅是超氧化物歧化酶和葡萄糖磷酸化过程中的酶催化剂,还影响氧化还原过程、渗透调节、新陈代谢和神经信号。然而,金属失衡会导致糖尿病等疾病,而糖尿病的特征是慢性高血糖,并影响伤口愈合。糖尿病的高血糖环境会影响伤口愈合,给患者的生活质量带来重大挑战。伤口愈合包括止血、炎症、增殖和重塑阶段的复杂级联,在高血糖条件下容易受到破坏。近几十年来,金属通过增强抗菌特性(如铁和银)、刺激血管生成(铜)、促进抗氧化活性和生长因子合成(锌)以及支持伤口闭合(钙和镁),成为伤口修复的重要促进因素。因此,研究重点转向开发基于金属离子的疗法,包括纳米水凝胶、纳米微针敷料和微针贴片等创新配方。通过将壳聚糖、透明质酸和海藻酸钠等高分子材料与金属结合制备,旨在改善糖尿病伤口的管理。本综述阐述了主要金属在人体生理中的作用,并评估了金属离子在糖尿病伤口管理策略中的应用。
{"title":"Metal ion formulations for diabetic wound healing: Mechanisms and therapeutic potential","authors":"Yuhe Dai ,&nbsp;Qianbo Zhang ,&nbsp;Rifang Gu ,&nbsp;Jitao Chen ,&nbsp;Penghui Ye ,&nbsp;Huan Zhu ,&nbsp;Ming Tang ,&nbsp;Xuqiang Nie","doi":"10.1016/j.ijpharm.2024.124889","DOIUrl":"10.1016/j.ijpharm.2024.124889","url":null,"abstract":"<div><div>Metals are vital in human physiology, which not only act as enzyme catalysts in the processes of superoxide dismutase and glucose phosphorylation, but also affect the redox process, osmotic adjustment, metabolism and neural signals. However, metal imbalances can lead to diseases such as diabetes, which is marked by chronic hyperglycemia and affects wound healing. The hyperglycemic milieu of diabetes impairs wound healing, posing significant challenges to patient quality of life. Wound healing encompasses a complex cascade of hemostasis, inflammation, proliferation, and remodeling phases, which are susceptible to disruption in hyperglycemic conditions. In recent decades, metals have emerged as critical facilitators of wound repair by enhancing antimicrobial properties (e.g., iron and silver), providing angiogenic stimulation (copper), promoting antioxidant activity and growth factor synthesis (zinc), and supporting wound closure (calcium and magnesium). Consequently, research has pivoted towards the development of metal ion-based therapeutics, including innovative formulations such as nano-hydrogels, nano-microneedle dressings, and microneedle patches. Prepared by combining macromolecular materials such as chitosan, hyaluronic acid and sodium alginate with metals, aiming at improving the management of diabetic wounds. This review delineates the roles of key metals in human physiology and evaluates the application of metal ions in diabetic wound management strategies.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124889"},"PeriodicalIF":5.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Launching triple-hit chemo attack on TNBC through nanoparticle-mediated codelivery of cisplatin-chlorambucil conjugate and venetoclax 通过纳米颗粒介导的顺铂-氯霉素共轭物和 Venetoclax 的联合给药,对 TNBC 发起三重打击化疗。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-29 DOI: 10.1016/j.ijpharm.2024.124890
Tushar Date, Oly Katari, Kaushik Kuche, Dasharath Chaudhari, Sanyog Jain
The BRCA1 dysfunction and HR deficiency in TNBC are responsible for high effectiveness of DNA-damaging agents in TNBC treatment. Preclinical and clinical studies confirmed the effectiveness of cisplatin in TNBC treatment. Nevertheless, the clinical utility of cisplatin is inadequate due to severe systemic side effects and resistance development. Dual-action cisplatin (IV) prodrugs provide an excellent opportunity to improve anticancer activity, reduce toxicities and minimize chance of resistance development. Therefore, in this investigation we have synthesized cisplatin-chlorambucil (CP-CBL) prodrug and loaded it with venetoclax (VTX) in phenylboronic acid conjugated TPGS-lactide nanoparticles (TNPs) to achieve tumor-targeted drug delivery thereby reducing the therapeutic dose as well as increasing the efficacy of free cisplatin, chlorambucil and venetoclax. The TNPs possessed particle size of 143 nm, PDI 0.186 and entrapment efficiency of 63.5 % and 56.4 % for VTX and CP-CBL. The TNPs followed Higuchi release kinetic model and represented biphasic release behaviour with early burst release of drug within 2 h succeeded by sustained drug release till 72 h. Further, the TNPs showed ∼ 42 folds and ∼ 19 folds reduction in the IC50 values compared to free CP. Also, higher cellular uptake and therefore greater apoptotic index was observed for the TNPs in comparison to the untargeted nanoparticles. The TNPs further showed higher ROS generating potential, enhanced mitochondrial membrane depolarization, higher intensity of nuclear condensation and highest level of caspase-3 expression. Moreover, a noteworthy decrease in the tumor volume was noticed in the mice treated with TNPs along with lower serum toxicity biomarker levels compared to the free drugs. Overall, the developed TNPs proved to be a promising and safer strategy for inducing triple-hit action in TNBC management.
TNBC 中的 BRCA1 功能障碍和 HR 缺乏是 DNA 损伤药物在 TNBC 治疗中发挥高效作用的原因。临床前和临床研究证实了顺铂在 TNBC 治疗中的有效性。然而,由于严重的全身副作用和耐药性的产生,顺铂的临床应用并不充分。双重作用的顺铂(IV)原药为提高抗癌活性、降低毒性和减少耐药性的产生提供了一个绝佳的机会。因此,在这项研究中,我们合成了顺铂-氯丁氨嘧啶(CP-CBL)原药,并将其与 Venetoclax(VTX)装入苯硼酸共轭 TPGS-内酰胺纳米颗粒(TNPs)中,实现了肿瘤靶向给药,从而降低了治疗剂量,提高了游离顺铂、氯丁氨嘧啶和 Venetoclax 的疗效。TNPs 的粒径为 143 nm,PDI 为 0.186,对 VTX 和 CP-CBL 的截留效率分别为 63.5% 和 56.4%。TNPs 遵循樋口释放动力学模型,表现为双相释放行为,药物在 2 小时内快速释放,随后药物持续释放至 72 小时。此外,与游离 CP 相比,TNPs 的 IC50 值分别降低了 42 倍和 19 倍。此外,与非靶向纳米粒子相比,TNPs 的细胞吸收率更高,因此凋亡指数也更高。TNPs 还显示出更高的 ROS 生成电位、线粒体膜去极化增强、核凝聚强度更高以及 Caspase-3 表达水平最高。此外,与游离药物相比,使用 TNPs 治疗的小鼠肿瘤体积明显缩小,血清毒性生物标志物水平也有所降低。总之,所开发的 TNPs 被证明是一种在 TNBC 治疗中诱导三击作用的前景广阔且更安全的策略。
{"title":"Launching triple-hit chemo attack on TNBC through nanoparticle-mediated codelivery of cisplatin-chlorambucil conjugate and venetoclax","authors":"Tushar Date,&nbsp;Oly Katari,&nbsp;Kaushik Kuche,&nbsp;Dasharath Chaudhari,&nbsp;Sanyog Jain","doi":"10.1016/j.ijpharm.2024.124890","DOIUrl":"10.1016/j.ijpharm.2024.124890","url":null,"abstract":"<div><div>The BRCA1 dysfunction and HR deficiency in TNBC are responsible for high effectiveness of DNA-damaging agents in TNBC treatment. Preclinical and clinical studies confirmed the effectiveness of cisplatin in TNBC treatment. Nevertheless, the clinical utility of cisplatin is inadequate due to severe systemic side effects and resistance development. Dual-action cisplatin (IV) prodrugs provide an excellent opportunity to improve anticancer activity, reduce toxicities and minimize chance of resistance development. Therefore, in this investigation we have synthesized cisplatin-chlorambucil (CP-CBL) prodrug and loaded it with venetoclax (VTX) in phenylboronic acid conjugated TPGS-lactide nanoparticles (TNPs) to achieve tumor-targeted drug delivery thereby reducing the therapeutic dose as well as increasing the efficacy of free cisplatin, chlorambucil and venetoclax. The TNPs possessed particle size of 143 nm, PDI 0.186 and entrapment efficiency of 63.5 % and 56.4 % for VTX and CP-CBL. The TNPs followed Higuchi release kinetic model and represented biphasic release behaviour with early burst release of drug within 2 h succeeded by sustained drug release till 72 h. Further, the TNPs showed ∼ 42 folds and ∼ 19 folds reduction in the IC<sub>50</sub> values compared to free CP. Also, higher cellular uptake and therefore greater apoptotic index was observed for the TNPs in comparison to the untargeted nanoparticles. The TNPs further showed higher ROS generating potential, enhanced mitochondrial membrane depolarization, higher intensity of nuclear condensation and highest level of caspase-3 expression. Moreover, a noteworthy decrease in the tumor volume was noticed in the mice treated with TNPs along with lower serum toxicity biomarker levels compared to the free drugs. Overall, the developed TNPs proved to be a promising and safer strategy for inducing triple-hit action in TNBC management.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124890"},"PeriodicalIF":5.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoinjector optimization through cavitation response and severity minimization 通过气蚀响应和严重程度最小化优化自动注射器。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-29 DOI: 10.1016/j.ijpharm.2024.124888
Tyler R. Kennelly, Sadegh Dabiri
Abrupt acceleration of the syringe of an autoinjector (AI) upon rod-plunger impact may induce undesired severe cavitation events and impose extraneous stresses upon the device, leading to device failure. Cavitation results from a rapid and significant pressure drop in a liquid, leading to the formation and growth of small vapor-filled cavities. Upon collapse, these cavities generate an intense shock wave that may lead to protein aggregation and device container damage and shatter. Since the maximum acceleration of the syringe depends upon the operating conditions of the AI, the severity of cavitation will likewise depend on the operating conditions of the AI. Likewise, injection time and ensuring proper needle displacement before drug release also depend on operating conditions, making optimization of the autoinjector a multiobjective optimization problem.
Therefore, in this study, optimization of an autoinjector to limit cavitation severity is pursued via an experimentally validated computational model for cavitation in spring-driven autoinjectors. Our goal is to locate AI design configurations that balance maximizing device performance and patient comfort and minimizing the risks of device damage and severe cavitation upon actuation.
Relevant parameters of interest are the drive spring force, air gap height, solution viscosity, friction between the rod and spring, frictional force on the plunger, rates of change of frictional force on the plunger, elasticity of plunger, viscosity of the plunger, and initial displacement between the plunger and the driving rod. The kinematics of the syringe barrel, needle displacement (travel distance) at the start of drug delivery, and injection time are gathered using an experimentally validated autoinjector kinematics model. At the same time, cavitation bubble dynamics are resolved using an experimentally validated cavitation model that takes the temporal displacement of the syringe and temporal air gap pressure as inputs.
We use our experimentally validated models to explore the parameter space and understand the driving factors of our desired outcomes. Subsequently, we pose the design problem as a multi-objective optimization problem and develop a deep neural network surrogate model supplemented with iterative learning to speed up optimization. A variance-based sensitivity analysis was performed to determine the sensitivity and influence of design parameters on the outcomes, and the main contributors to the outcomes of interest were isolated. Using a multi-objective optimization framework, we located 300 + successful candidates and evaluated them through uncertainty analysis to identify three promising candidates that meet all criteria for drug viscosities of interest. Finally, we show that this methodology can be used to conduct hypothesis testing, leading to novel design configurations.
自动注射器(AI)的注射器在受到杆柱塞撞击时突然加速,可能会诱发不希望发生的严重空化现象,并对设备造成额外的应力,从而导致设备故障。气蚀是由于液体中的压力急剧下降,导致充满蒸汽的小空腔形成和增大。塌陷时,这些空腔会产生强烈的冲击波,可能导致蛋白质聚集、装置容器损坏和破碎。由于注射器的最大加速度取决于人工智能的操作条件,因此空化的严重程度也同样取决于人工智能的操作条件。同样,注射时间和确保药物释放前针头的适当位移也取决于操作条件,因此自动注射器的优化是一个多目标优化问题。因此,在本研究中,我们将通过经实验验证的弹簧驱动自动注射器气蚀计算模型,对自动注射器进行优化,以限制气蚀的严重程度。我们的目标是找到人工智能设计配置,在设备性能和患者舒适度最大化与设备损坏和启动时严重气蚀风险最小化之间取得平衡。相关参数包括驱动弹簧力、气隙高度、溶液粘度、杆和弹簧之间的摩擦力、柱塞上的摩擦力、柱塞上摩擦力的变化率、柱塞的弹性、柱塞的粘度以及柱塞和驱动杆之间的初始位移。通过实验验证的自动注射器运动学模型,收集了注射器枪管的运动学特性、开始给药时针头的位移(移动距离)和注射时间。与此同时,我们还利用实验验证的空化模型解析了空化气泡动力学,该模型将注射器的时间位移和时间气隙压力作为输入。我们利用经过实验验证的模型来探索参数空间,了解我们所期望的结果的驱动因素。随后,我们将设计问题作为一个多目标优化问题,并开发了一个深度神经网络代用模型,辅以迭代学习来加快优化速度。我们进行了基于方差的敏感性分析,以确定设计参数对结果的敏感性和影响,并分离出导致相关结果的主要因素。利用多目标优化框架,我们找到了 300 + 个成功的候选方案,并通过不确定性分析对它们进行了评估,最终确定了三个有希望的候选方案,它们符合相关药物粘度的所有标准。最后,我们展示了这种方法可用于进行假设检验,从而产生新的设计配置。
{"title":"Autoinjector optimization through cavitation response and severity minimization","authors":"Tyler R. Kennelly,&nbsp;Sadegh Dabiri","doi":"10.1016/j.ijpharm.2024.124888","DOIUrl":"10.1016/j.ijpharm.2024.124888","url":null,"abstract":"<div><div>Abrupt acceleration of the syringe of an autoinjector (AI) upon rod-plunger impact may induce undesired severe cavitation events and impose extraneous stresses upon the device, leading to device failure. Cavitation results from a rapid and significant pressure drop in a liquid, leading to the formation and growth of small vapor-filled cavities. Upon collapse, these cavities generate an intense shock wave that may lead to protein aggregation and device container damage and shatter. Since the maximum acceleration of the syringe depends upon the operating conditions of the AI, the severity of cavitation will likewise depend on the operating conditions of the AI. Likewise, injection time and ensuring proper needle displacement before drug release also depend on operating conditions, making optimization of the autoinjector a multiobjective optimization problem.</div><div>Therefore, in this study, optimization of an autoinjector to limit cavitation severity is pursued via an experimentally validated computational model for cavitation in spring-driven autoinjectors. Our goal is to locate AI design configurations that balance maximizing device performance and patient comfort and minimizing the risks of device damage and severe cavitation upon actuation.</div><div>Relevant parameters of interest are the drive spring force, air gap height, solution viscosity, friction between the rod and spring, frictional force on the plunger, rates of change of frictional force on the plunger, elasticity of plunger, viscosity of the plunger, and initial displacement between the plunger and the driving rod. The kinematics of the syringe barrel, needle displacement (travel distance) at the start of drug delivery, and injection time are gathered using an experimentally validated autoinjector kinematics model. At the same time, cavitation bubble dynamics are resolved using an experimentally validated cavitation model that takes the temporal displacement of the syringe and temporal air gap pressure as inputs.</div><div>We use our experimentally validated models to explore the parameter space and understand the driving factors of our desired outcomes. Subsequently, we pose the design problem as a multi-objective optimization problem and develop a deep neural network surrogate model supplemented with iterative learning to speed up optimization. A variance-based sensitivity analysis was performed to determine the sensitivity and influence of design parameters on the outcomes, and the main contributors to the outcomes of interest were isolated. Using a multi-objective optimization framework, we located 300 + successful candidates and evaluated them through uncertainty analysis to identify three promising candidates that meet all criteria for drug viscosities of interest. Finally, we show that this methodology can be used to conduct hypothesis testing, leading to novel design configurations.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124888"},"PeriodicalIF":5.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biochanin-A co-crystal formulation improves bioavailability and ameliorates cerulein-induced pancreatitis by attenuating the inflammation 生物chanin-A共晶体制剂提高了生物利用度,并通过减轻炎症改善了脑磷脂诱发的胰腺炎。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.1016/j.ijpharm.2024.124874
Hari Priya Sripadi , Rajwinder Kaur , Saylee Manohar Koli , Nidhi Sharma , Vijaya Sarathi U.V.R. , Jagadeesh Babu Nanubolu , Sai Balaji Andugulapati , Ramakrishna Sistla
Co-crystallization of a therapeutic ingredient with an appropriate co-former is a powerful technique to augment the physicochemical and pharmacokinetic properties and the effectiveness of Active Pharmaceutical Ingredients (APIs). Biochanin A (BCA), a flavonoid with medicinal potential, is limited by poor solubility and low oral bioavailability. This study aimed to design and develop a novel BCA-nicotinamide cocrystal as BCC to enhance BCA’s oral bioavailability and explore its therapeutic potential for ameliorating cerulein-induced acute pancreatitis (CIAP) by elucidating the target identification utilizing tissue/serum metabolite profiles. The cocrystal was designed by the supramolecular synthon approach and characterized by single-crystal X-ray diffraction that confirms a robust three-dimensional hydrogen-bonded network of BCA and Nicotinamide (NCT) in the crystal. FT-IR and DSC were used to analyze the cocrystal’s intermolecular interactions and thermal behavior. BCC exhibited enhanced solubility and drug release compared to BCA alone, resulting in enhanced oral bioavailability and pancreatic tissue concentration. Comparing BCC to BCA in the CIAP model, BCC therapy remarkably reduced cerulein-induced pancreatitis, evidenced by significant reductions in inflammation, acinar cell atrophy, and amylase levels in pancreatic tissues. Further, the cocrystal formulation also down-regulated the oxidative stress markers, inflammatory cytokines and macrophage-related proteins. The study has identified distinct metabolomic signatures linked with AP with the help of Orbitrap Exploris mass spectrometry, which could pave the way for creating focused diagnostic tools for a better prognosis. In conclusion, these results offer new insights into exploring mechanistic pathways associated with specific biomarkers and underscore BCC cocrystal as a promising approach to enhance BCA’s therapeutic potential.
将治疗成分与适当的共形成剂进行共结晶是一种强大的技术,可增强活性药物成分(APIs)的物理化学和药代动力学特性及有效性。生物黄酮 A(BCA)是一种具有药用潜力的黄酮类化合物,但其溶解性差,口服生物利用度低。本研究旨在设计和开发一种新型 BCA-烟酰胺共晶体作为 BCC,以提高 BCA 的口服生物利用度,并通过利用组织/血清代谢物图谱阐明目标识别,探索其在改善脑磷脂诱导的急性胰腺炎(CIAP)方面的治疗潜力。该共晶体是通过超分子合成方法设计的,并通过单晶 X 射线衍射进行了表征,证实晶体中 BCA 和烟酰胺(NCT)形成了稳固的三维氢键网络。傅立叶变换红外光谱(FT-IR)和 DSC 用于分析共晶体的分子间相互作用和热行为。与单独的 BCA 相比,BCC 表现出更强的溶解性和药物释放性,从而提高了口服生物利用度和胰腺组织浓度。在CIAP模型中,将BCC与BCA进行比较,BCC疗法明显减轻了脑磷脂诱发的胰腺炎,这体现在胰腺组织的炎症、胰腺细胞萎缩和淀粉酶水平显著降低。此外,共晶制剂还能下调氧化应激标记物、炎症细胞因子和巨噬细胞相关蛋白。该研究借助 Orbitrap Exploris 质谱仪确定了与 AP 相关的独特代谢组学特征,这为开发重点诊断工具以改善预后铺平了道路。总之,这些结果为探索与特定生物标志物相关的机理途径提供了新的见解,并强调了 BCC 共晶体是提高 BCA 治疗潜力的一种有前途的方法。
{"title":"Biochanin-A co-crystal formulation improves bioavailability and ameliorates cerulein-induced pancreatitis by attenuating the inflammation","authors":"Hari Priya Sripadi ,&nbsp;Rajwinder Kaur ,&nbsp;Saylee Manohar Koli ,&nbsp;Nidhi Sharma ,&nbsp;Vijaya Sarathi U.V.R. ,&nbsp;Jagadeesh Babu Nanubolu ,&nbsp;Sai Balaji Andugulapati ,&nbsp;Ramakrishna Sistla","doi":"10.1016/j.ijpharm.2024.124874","DOIUrl":"10.1016/j.ijpharm.2024.124874","url":null,"abstract":"<div><div>Co-crystallization of a therapeutic ingredient with an appropriate co-former is a powerful technique to augment the physicochemical and pharmacokinetic properties and the effectiveness of Active Pharmaceutical Ingredients (APIs). Biochanin A (BCA), a flavonoid with medicinal potential, is limited by poor solubility and low oral bioavailability. This study aimed to design and develop a novel BCA-nicotinamide cocrystal as BCC to enhance BCA’s oral bioavailability and explore its therapeutic potential for ameliorating cerulein-induced acute pancreatitis (CIAP) by elucidating the target identification utilizing tissue/serum metabolite profiles. The cocrystal was designed by the supramolecular synthon approach and characterized by single-crystal X-ray diffraction that confirms a robust three-dimensional hydrogen-bonded network of BCA and Nicotinamide (NCT) in the crystal. FT-IR and DSC were used to analyze the cocrystal’s intermolecular interactions and thermal behavior. BCC exhibited enhanced solubility and drug release compared to BCA alone, resulting in enhanced oral bioavailability and pancreatic tissue concentration. Comparing BCC to BCA in the CIAP model, BCC therapy remarkably reduced cerulein-induced pancreatitis, evidenced by significant reductions in inflammation, acinar cell atrophy, and amylase levels in pancreatic tissues. Further, the cocrystal formulation also down-regulated the oxidative stress markers, inflammatory cytokines and macrophage-related proteins. The study has identified distinct metabolomic signatures linked with AP with the help of Orbitrap Exploris mass spectrometry, which could pave the way for creating focused diagnostic tools for a better prognosis. In conclusion, these results offer new insights into exploring mechanistic pathways associated with specific biomarkers and underscore BCC cocrystal as a promising approach to enhance BCA’s therapeutic potential.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124874"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vasculo-osteogenic keratin-based nanofibers containing merwinite nanoparticles and sildenafil for bone tissue regeneration 用于骨组织再生的含有美尔维尼纳米颗粒和西地那非的血管促生长角蛋白基纳米纤维。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.1016/j.ijpharm.2024.124875
Basma Talib Al-Sudani , Mastafa H. Al-Musawi , Marwa M. Kamil , Sumyah H. Turki , Sepideh Nasiri- Harchegani , Aliakbar Najafinezhad , Parastoo Noory , Sina Talebi , Hamideh Valizadeh , Fariborz Sharifianjazi , Leila Bazli , Mohamadreza Tavakoli , Morteza Mehrjoo , Mahboubeh Firuzeh , Marjan Mirhaj
Vascularization of bone tissue constructs plays a pivotal role in facilitating nutrient transport and metabolic waste removal during the processes of osteogenesis and bone regeneration in vivo. In this study, a sildenafil (Sil)-loaded nanofibrous scaffold of keratin/Soluplus/merwinite (KS.Me.Sil) was fabricated through electrospinning and the effectiveness of the scaffold was assessed for bone tissue engineering applications. The KS.Me.Sil nanofibrous scaffold exhibited notably enhanced ultimate tensile strength (3.38 vs 2.61 MPa) and elastic modulus (69.83 vs 46.27 MPa) compared to the KS scaffold. The in vitro release of Ca2+, Si4+ and Mg2+ ions and the release of Sil from the nanofibers as well as biodegradability and bioactivity were evaluated for 14 days. Protein adsorption capability and cytocompatibility of the scaffolds were tested. Alkaline phosphatase activity test, Alizarin red staining and qRT-PCR analysis demonstrated that the KS.Me.Sil nanofibers had the best osteogenic activity among other samples. Also, the results of the chorioallantoic membrane assay showed an almost threefold increase in blood vessel density in the group treated with the KS.Me.Sil nanofibers extract compared to the KS. In conclusion, our findings suggest that the electrospun KS.Me.Sil nanofibrous scaffold offers a robust structure with exceptional osteogenic and angiogenic characteristics, making it a promising candidate for bone tissue engineering applications.
在体内成骨和骨再生过程中,骨组织结构的血管化在促进营养运输和代谢废物清除方面发挥着关键作用。本研究通过电纺丝技术制备了负载西地那非(Sil)的角蛋白/Soluplus/merwinite(KS.Me.Sil)纳米纤维支架,并评估了该支架在骨组织工程应用中的有效性。与 KS 支架相比,KS.Me.Sil 纳米纤维支架的极限拉伸强度(3.38 对 2.61 兆帕)和弹性模量(69.83 对 46.27 兆帕)明显提高。对纳米纤维的 Ca2+、Si4+ 和 Mg2+ 离子体外释放量、硅释放量、生物降解性和生物活性进行了为期 14 天的评估。测试了支架的蛋白质吸附能力和细胞相容性。碱性磷酸酶活性测试、茜素红染色和 qRT-PCR 分析表明,在其他样品中,KS.Me.Sil 纳米纤维的成骨活性最好。此外,绒毛膜检测结果表明,与 KS 相比,使用 KS.Me.Sil 纳米纤维提取物处理的组的血管密度增加了近三倍。总之,我们的研究结果表明,电纺 KS.Me.Sil 纳米纤维支架结构坚固,具有优异的成骨和血管生成特性,是骨组织工程应用的理想候选材料。
{"title":"Vasculo-osteogenic keratin-based nanofibers containing merwinite nanoparticles and sildenafil for bone tissue regeneration","authors":"Basma Talib Al-Sudani ,&nbsp;Mastafa H. Al-Musawi ,&nbsp;Marwa M. Kamil ,&nbsp;Sumyah H. Turki ,&nbsp;Sepideh Nasiri- Harchegani ,&nbsp;Aliakbar Najafinezhad ,&nbsp;Parastoo Noory ,&nbsp;Sina Talebi ,&nbsp;Hamideh Valizadeh ,&nbsp;Fariborz Sharifianjazi ,&nbsp;Leila Bazli ,&nbsp;Mohamadreza Tavakoli ,&nbsp;Morteza Mehrjoo ,&nbsp;Mahboubeh Firuzeh ,&nbsp;Marjan Mirhaj","doi":"10.1016/j.ijpharm.2024.124875","DOIUrl":"10.1016/j.ijpharm.2024.124875","url":null,"abstract":"<div><div>Vascularization of bone tissue constructs plays a pivotal role in facilitating nutrient transport and metabolic waste removal during the processes of osteogenesis and bone regeneration <em>in vivo</em>. In this study, a sildenafil (Sil)-loaded nanofibrous scaffold of keratin/Soluplus/merwinite (KS.Me.Sil) was fabricated through electrospinning and the effectiveness of the scaffold was assessed for bone tissue engineering applications. The KS.Me.Sil nanofibrous scaffold exhibited notably enhanced ultimate tensile strength (3.38 vs 2.61 MPa) and elastic modulus (69.83 vs 46.27 MPa) compared to the KS scaffold. The <em>in vitro</em> release of Ca<sup>2+</sup>, Si<sup>4+</sup> and Mg<sup>2+</sup> ions and the release of Sil from the nanofibers as well as biodegradability and bioactivity were evaluated for 14 days. Protein adsorption capability and cytocompatibility of the scaffolds were tested. Alkaline phosphatase activity test, Alizarin red staining and qRT-PCR analysis demonstrated that the KS.Me.Sil nanofibers had the best osteogenic activity among other samples. Also, the results of the chorioallantoic membrane assay showed an almost threefold increase in blood vessel density in the group treated with the KS.Me.Sil nanofibers extract compared to the KS. In conclusion, our findings suggest that the electrospun KS.Me.Sil nanofibrous scaffold offers a robust structure with exceptional osteogenic and angiogenic characteristics, making it a promising candidate for bone tissue engineering applications.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"667 ","pages":"Article 124875"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Pharmaceutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1